Bagsværd, Denmark, 9 December 2015 - Novo Nordisk today announced the submission of the New Drug Application (NDA) for faster-acting insulin aspart to the US Food and Drug Administration (FDA). Faster ...

HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...

Bagsværd, Denmark, 10 January 2017 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Fiasp ® for the treatment of diabetes in adults. The ...

Expert Rev Endocrinol Metab. 2010;5(4):507-516. The 'Summary of Product Characteristics' for BIAsp 30 has recently been changed to reflect data from the clinical trial program. These data showed that ...

Biocon Biologics and Civica announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Under the terms of the agreement, Biocon Biologics ...

Insulin Aspart (Novomix 30 Flexpen 100IU/ml) is a fast-acting form of the hormone insulin, prescribed for diabetes mellitus. It is used with other medium- or long-acting insulin products injected just ...

Background: Insulin analogues may be associated with fewer episodes of hypoglycemia than conventional insulins. However, they are costly alternatives. We compared the cost-effectiveness of insulin ...

Drugmaker Wockhardt has approached the Drug Controller General of India (DCGI) seeking approvals for its fast-acting insulin analog, Aspart injection. The company’s Aspart insulin injection ...

Insulin is an essential medicine that helps the body turn food into energy and regulate blood sugar levels for millions of people with diabetes nationwide. That makes access to insulin vital for ...

The Business Research Company's Insulin Aspart Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Save 30% On All Global Market Reports With Code ONLINE30 – Stay Informed ...